|
article-title
|
COVID-19-associated invasive pulmonary aspergillosis
|
|
body
|
To the Editor:
Since March 2020, following in the footsteps of China, Europe has been facing the COVID-19 pandemic, caused by the SARS-COV-2 virus [1]. Increasing numbers of patients are being admitted to intensive care units (ICU) throughout the world, imposing multiple diagnostic and therapeutic challenges on stressed healthcare systems. In our 24-bedded mixed ICU, we have encountered an unexpectedly high number of COVID-19 patients developing invasive pulmonary aspergillosis. Through our case series, we aim to raise awareness of this severe complication in the critical care community, point out different diagnostic obstacles and share our approach to the management of this complex problem.
Invasive pulmonary aspergillosis (IPA) is a well-known complication in immunocompromised patients and is encountered frequently in haematopoietic stem cell or solid organ transplant recipients [2]. Continued improvement in diagnostics has revealed that half of the cases of IPA occur in the ICU, in patients who are often non-neutropenic [3, 4]. Severe influenza infection is a well-known risk factor for developing IPA in non-neutropenic patients; a syndrome termed influenza-associated aspergillosis (IAA) [4–6]. A damaged respiratory epithelium, dysfunctional mucociliary clearance and a local immune paralysis were demonstrated to be key pathophysiological factors [4]. Supported by the hypothesis that alveolar damage facilitates fungal invasion, acute respiratory distress syndrome (ARDS) has frequently been associated with IPA in the ICU [6]. With this in mind, the existence of COVID-19-associated pulmonary aspergillosis is deemed likely.
Between March 12th and April 25th 2020, 34 COVID-19 patients were admitted to our ICU, of whom 20 (59%) required invasive mechanical ventilation. Seven of these ventilated patients (35%) were suspected of IPA (Table 1). Median age in our patient cohort was 66 (interquartile range 56–77) years. Underlying comorbidities were primarily cardiovascular. Only three patients were immunocompromised. One patient received chronic corticosteroid treatment for pemphigus foliaceous, one patient was HIV-positive (CD4 count > 250; viral load < 20 copies, treated with antiretrovirals [lamivudine/tenofovir/nevirapine]) and one patient had been treated for acute myeloid leukaemia 8 years ago and had developed IPA during chemotherapy. All patients were intubated and mechanically ventilated due to severe COVID-19 pneumonia.
Table 1 Patients with suspected IPA
Patient ID Sex (M/F) Age Medical history Time between COVID-19 symptoms and ICU admission (days) Time between COVID-19 symptoms and intubation (days) Time between intubation and first finding of IPA (days) First BAL galactomannan index Peak BAL galactomannan index First serum galactomannan index Peak serum galactomannan index
1 M 86 Hyperchol 7 7 9 N/A N/A 0.10 0.10
2 M 38 Obesity, hyperchol 9 9 6 2.40 > 2.80 0.30 0.30
3 M 62 DM 7 7 16 0.72 2.00 0.20 0.20
4 M 73 DM, obesity, AHT, hyperchol 9 10 5 2.65 > 2.80 0.10 0.10
5 M 77 DM, CKD, AHT, pemphigus foliaceus 9 10 2 2.79 2.79 0.10 0.10
6 M 55 HIV, AHT, hyperchol 8 9 13 0.69 0.69 0.18 0.80
7 M 75 AML, IPA (2012) 3 3 8 2.63 2.63 N/A N/A
Patient ID Sex (M/F) Age Medical history First positive culture CT scan Histological examinationa IPA diagnosis AspICU algorithm Antifungal therapy Outcome
1 M 86 Hyperchol A. flavus (ETA) No scan available N/A – – None Died, ICU day 10
2 M 38 Obesity, hyperchol A. fumigatus (BAL) + Positive Proven Absolute Voriconazole, isavuconazole Alive on MV, ICU day 28b
3 M 62 DM A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Died, ICU day 20
4 M 73 DM, obesity, AHT, hyperchol A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Alive on MV, ICU day 24b
5 M 77 DM, CKD, AHT, pemphigus foliaceus A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Alive on MV, ICU day 21b
6 M 55 HIV, AHT, hyperchol Negative No scan available Negative – Voriconazole, isavuconazole Died, ICU day 27
7 M 75 AML, IPA (2012) A. fumigatus (BAL) No scan available N/A – Voriconazole Died, ICU day 8
CKD chronic kidney disease, AML acute myeloid leukaemia, IPA invasive pulmonary aspergillosis. N/A no sample available, Hyperchol hypercholesterolaemia, AHT arterial hypertension, DM diabetes mellitus, BAL bronchoalveolar lavage, ETA endotracheal aspirate, MV mechanical ventilation arterial hypertension
aAnatomopathological examination of tissue samples obtained via bronchoscopy
bAt the time of writing
Our suspicion was raised initially through an unusually rapid growth (< 48 h) of Aspergillus species in bronchial aspirates of three different patients. All samples were obtained during routine bronchoscopies, performed for atelectasis, respiratory deterioration or increasing inflammatory parameters. From that moment, routine galactomannan assays on serum and bronchoalveolar lavage (BAL) fluid were assessed regularly and bronchoscopy-guided biopsies of suspicious tracheobronchial lesions were obtained whenever present. Unfortunately, computed tomography (CT) scanning was deemed unfeasible in some patients due to extreme hypoxia or difficult mechanical ventilation and whenever performed, the distinction between COVID-19 and Aspergillus lesions proved complex.
Table 1 shows the timing and results of the microbiological testing in our case series. Differentiating between Aspergillus colonization and IPA is notoriously difficult, especially in the ICU. In the absence of host factors, as defined by the European Organisation for Research and Treatment of Cancer (EORTC) diagnostic criteria, invasive or high-risk diagnostics (biopsy, CT scan) are required to support the diagnosis of IPA [7]. The AspICU algorithm was designed to partially deal with the absence of host factors [6]. Based on this algorithm, four patients (No 2, 3, 4, 5) were diagnosed with proven IPA, based on histopathological evidence. All of these patients showed positive galactomannan indices on BAL fluid. In two patients, cultures and/or galactomannan BAL only became positive post mortem (No 1, 7), before CT scan or histopathological samples could be obtained. In one patient (No 6), histopathological sampling was negative and galactomannan BAL only mildly raised, but a raised serum galactomannan was later detected. In the remaining patients, the serum galactomannan index remained negative (< 0.5). The mean time between intubation date and the first microbiological signs of IPA was a striking 8 (SD 5) days.
ICU physicians often have to weigh the risks of further diagnostic tests against a delayed initiation of antifungal treatment, which is associated with mortality rates over 65% [6]. Because all patients with clinical features of possible IPA were suffering from severe respiratory failure and hemodynamic instability, we initiated antifungal therapy as soon as cultures or galactomannan assays were positive. Five patients were started on voriconazole. In two of these patients, the treatment was escalated to isavuconazole due to pancytopenia or undetectable voriconazole levels under continuous renal replacement therapy. Two patients died on treatment.
To confirm and control this alarming incidence of COVID-19-associated IPA, a number of measures were taken. Firstly, we ruled out an environmental source, by sampling room air and the oxygen and pressurized air supplies (MAS 100, Merck). Prior to COVID-19, the incidence of IPA in our ICU was not elevated. Nonetheless, high-efficiency particulate air filters (HEPA) (Halton Vita, Helsinki, Finland) were installed in the ICU. Secondly, all mechanically ventilated COVID-19 patients were screened systematically by performing serum galactomannan assays twice weekly. Whenever a bronchoscopy was needed, BAL galactomannan indices and mould cultures were requested, regardless of the indication for bronchoscopy. Finally, we initiated prophylactic nebulization of 12.5 mg of liposomal amphotericin B (Ambisome®, Gilead, Foster City, USA) in every mechanically ventilated patient without an established diagnosis of IPA [8]. Since the implementation of these measures, we have not encountered any new cases of IPA at the time of writing.
Conclusion
Using this case series, we would like to raise awareness about COVID-19-associated pulmonary aspergillosis, in view of its potential detrimental outcome. We believe that a low threshold for screening, prophylaxis and early antifungal treatment is of paramount importance, especially since different immunosuppressive therapies have been suggested to treat patients suffering from this alarming condition.
|
|
p
|
To the Editor:
|
|
p
|
Since March 2020, following in the footsteps of China, Europe has been facing the COVID-19 pandemic, caused by the SARS-COV-2 virus [1]. Increasing numbers of patients are being admitted to intensive care units (ICU) throughout the world, imposing multiple diagnostic and therapeutic challenges on stressed healthcare systems. In our 24-bedded mixed ICU, we have encountered an unexpectedly high number of COVID-19 patients developing invasive pulmonary aspergillosis. Through our case series, we aim to raise awareness of this severe complication in the critical care community, point out different diagnostic obstacles and share our approach to the management of this complex problem.
|
|
p
|
Invasive pulmonary aspergillosis (IPA) is a well-known complication in immunocompromised patients and is encountered frequently in haematopoietic stem cell or solid organ transplant recipients [2]. Continued improvement in diagnostics has revealed that half of the cases of IPA occur in the ICU, in patients who are often non-neutropenic [3, 4]. Severe influenza infection is a well-known risk factor for developing IPA in non-neutropenic patients; a syndrome termed influenza-associated aspergillosis (IAA) [4–6]. A damaged respiratory epithelium, dysfunctional mucociliary clearance and a local immune paralysis were demonstrated to be key pathophysiological factors [4]. Supported by the hypothesis that alveolar damage facilitates fungal invasion, acute respiratory distress syndrome (ARDS) has frequently been associated with IPA in the ICU [6]. With this in mind, the existence of COVID-19-associated pulmonary aspergillosis is deemed likely.
|
|
p
|
Between March 12th and April 25th 2020, 34 COVID-19 patients were admitted to our ICU, of whom 20 (59%) required invasive mechanical ventilation. Seven of these ventilated patients (35%) were suspected of IPA (Table 1). Median age in our patient cohort was 66 (interquartile range 56–77) years. Underlying comorbidities were primarily cardiovascular. Only three patients were immunocompromised. One patient received chronic corticosteroid treatment for pemphigus foliaceous, one patient was HIV-positive (CD4 count > 250; viral load < 20 copies, treated with antiretrovirals [lamivudine/tenofovir/nevirapine]) and one patient had been treated for acute myeloid leukaemia 8 years ago and had developed IPA during chemotherapy. All patients were intubated and mechanically ventilated due to severe COVID-19 pneumonia.
Table 1 Patients with suspected IPA
Patient ID Sex (M/F) Age Medical history Time between COVID-19 symptoms and ICU admission (days) Time between COVID-19 symptoms and intubation (days) Time between intubation and first finding of IPA (days) First BAL galactomannan index Peak BAL galactomannan index First serum galactomannan index Peak serum galactomannan index
1 M 86 Hyperchol 7 7 9 N/A N/A 0.10 0.10
2 M 38 Obesity, hyperchol 9 9 6 2.40 > 2.80 0.30 0.30
3 M 62 DM 7 7 16 0.72 2.00 0.20 0.20
4 M 73 DM, obesity, AHT, hyperchol 9 10 5 2.65 > 2.80 0.10 0.10
5 M 77 DM, CKD, AHT, pemphigus foliaceus 9 10 2 2.79 2.79 0.10 0.10
6 M 55 HIV, AHT, hyperchol 8 9 13 0.69 0.69 0.18 0.80
7 M 75 AML, IPA (2012) 3 3 8 2.63 2.63 N/A N/A
Patient ID Sex (M/F) Age Medical history First positive culture CT scan Histological examinationa IPA diagnosis AspICU algorithm Antifungal therapy Outcome
1 M 86 Hyperchol A. flavus (ETA) No scan available N/A – – None Died, ICU day 10
2 M 38 Obesity, hyperchol A. fumigatus (BAL) + Positive Proven Absolute Voriconazole, isavuconazole Alive on MV, ICU day 28b
3 M 62 DM A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Died, ICU day 20
4 M 73 DM, obesity, AHT, hyperchol A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Alive on MV, ICU day 24b
5 M 77 DM, CKD, AHT, pemphigus foliaceus A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Alive on MV, ICU day 21b
6 M 55 HIV, AHT, hyperchol Negative No scan available Negative – Voriconazole, isavuconazole Died, ICU day 27
7 M 75 AML, IPA (2012) A. fumigatus (BAL) No scan available N/A – Voriconazole Died, ICU day 8
CKD chronic kidney disease, AML acute myeloid leukaemia, IPA invasive pulmonary aspergillosis. N/A no sample available, Hyperchol hypercholesterolaemia, AHT arterial hypertension, DM diabetes mellitus, BAL bronchoalveolar lavage, ETA endotracheal aspirate, MV mechanical ventilation arterial hypertension
aAnatomopathological examination of tissue samples obtained via bronchoscopy
bAt the time of writing
|
|
table-wrap
|
Table 1 Patients with suspected IPA
Patient ID Sex (M/F) Age Medical history Time between COVID-19 symptoms and ICU admission (days) Time between COVID-19 symptoms and intubation (days) Time between intubation and first finding of IPA (days) First BAL galactomannan index Peak BAL galactomannan index First serum galactomannan index Peak serum galactomannan index
1 M 86 Hyperchol 7 7 9 N/A N/A 0.10 0.10
2 M 38 Obesity, hyperchol 9 9 6 2.40 > 2.80 0.30 0.30
3 M 62 DM 7 7 16 0.72 2.00 0.20 0.20
4 M 73 DM, obesity, AHT, hyperchol 9 10 5 2.65 > 2.80 0.10 0.10
5 M 77 DM, CKD, AHT, pemphigus foliaceus 9 10 2 2.79 2.79 0.10 0.10
6 M 55 HIV, AHT, hyperchol 8 9 13 0.69 0.69 0.18 0.80
7 M 75 AML, IPA (2012) 3 3 8 2.63 2.63 N/A N/A
Patient ID Sex (M/F) Age Medical history First positive culture CT scan Histological examinationa IPA diagnosis AspICU algorithm Antifungal therapy Outcome
1 M 86 Hyperchol A. flavus (ETA) No scan available N/A – – None Died, ICU day 10
2 M 38 Obesity, hyperchol A. fumigatus (BAL) + Positive Proven Absolute Voriconazole, isavuconazole Alive on MV, ICU day 28b
3 M 62 DM A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Died, ICU day 20
4 M 73 DM, obesity, AHT, hyperchol A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Alive on MV, ICU day 24b
5 M 77 DM, CKD, AHT, pemphigus foliaceus A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Alive on MV, ICU day 21b
6 M 55 HIV, AHT, hyperchol Negative No scan available Negative – Voriconazole, isavuconazole Died, ICU day 27
7 M 75 AML, IPA (2012) A. fumigatus (BAL) No scan available N/A – Voriconazole Died, ICU day 8
CKD chronic kidney disease, AML acute myeloid leukaemia, IPA invasive pulmonary aspergillosis. N/A no sample available, Hyperchol hypercholesterolaemia, AHT arterial hypertension, DM diabetes mellitus, BAL bronchoalveolar lavage, ETA endotracheal aspirate, MV mechanical ventilation arterial hypertension
aAnatomopathological examination of tissue samples obtained via bronchoscopy
bAt the time of writing
|
|
label
|
Table 1
|
|
caption
|
Patients with suspected IPA
|
|
p
|
Patients with suspected IPA
|
|
table
|
Patient ID Sex (M/F) Age Medical history Time between COVID-19 symptoms and ICU admission (days) Time between COVID-19 symptoms and intubation (days) Time between intubation and first finding of IPA (days) First BAL galactomannan index Peak BAL galactomannan index First serum galactomannan index Peak serum galactomannan index
1 M 86 Hyperchol 7 7 9 N/A N/A 0.10 0.10
2 M 38 Obesity, hyperchol 9 9 6 2.40 > 2.80 0.30 0.30
3 M 62 DM 7 7 16 0.72 2.00 0.20 0.20
4 M 73 DM, obesity, AHT, hyperchol 9 10 5 2.65 > 2.80 0.10 0.10
5 M 77 DM, CKD, AHT, pemphigus foliaceus 9 10 2 2.79 2.79 0.10 0.10
6 M 55 HIV, AHT, hyperchol 8 9 13 0.69 0.69 0.18 0.80
7 M 75 AML, IPA (2012) 3 3 8 2.63 2.63 N/A N/A
|
|
tr
|
Patient ID Sex (M/F) Age Medical history Time between COVID-19 symptoms and ICU admission (days) Time between COVID-19 symptoms and intubation (days) Time between intubation and first finding of IPA (days) First BAL galactomannan index Peak BAL galactomannan index First serum galactomannan index Peak serum galactomannan index
|
|
th
|
Patient ID
|
|
th
|
Sex (M/F)
|
|
th
|
Age
|
|
th
|
Medical history
|
|
th
|
Time between COVID-19 symptoms and ICU admission (days)
|
|
th
|
Time between COVID-19 symptoms and intubation (days)
|
|
th
|
Time between intubation and first finding of IPA (days)
|
|
th
|
First BAL galactomannan index
|
|
th
|
Peak BAL galactomannan index
|
|
th
|
First serum galactomannan index
|
|
th
|
Peak serum galactomannan index
|
|
tr
|
1 M 86 Hyperchol 7 7 9 N/A N/A 0.10 0.10
|
|
td
|
1
|
|
td
|
M
|
|
td
|
86
|
|
td
|
Hyperchol
|
|
td
|
7
|
|
td
|
7
|
|
td
|
9
|
|
td
|
N/A
|
|
td
|
N/A
|
|
td
|
0.10
|
|
td
|
0.10
|
|
tr
|
2 M 38 Obesity, hyperchol 9 9 6 2.40 > 2.80 0.30 0.30
|
|
td
|
2
|
|
td
|
M
|
|
td
|
38
|
|
td
|
Obesity, hyperchol
|
|
td
|
9
|
|
td
|
9
|
|
td
|
6
|
|
td
|
2.40
|
|
td
|
> 2.80
|
|
td
|
0.30
|
|
td
|
0.30
|
|
tr
|
3 M 62 DM 7 7 16 0.72 2.00 0.20 0.20
|
|
td
|
3
|
|
td
|
M
|
|
td
|
62
|
|
td
|
DM
|
|
td
|
7
|
|
td
|
7
|
|
td
|
16
|
|
td
|
0.72
|
|
td
|
2.00
|
|
td
|
0.20
|
|
td
|
0.20
|
|
tr
|
4 M 73 DM, obesity, AHT, hyperchol 9 10 5 2.65 > 2.80 0.10 0.10
|
|
td
|
4
|
|
td
|
M
|
|
td
|
73
|
|
td
|
DM, obesity, AHT, hyperchol
|
|
td
|
9
|
|
td
|
10
|
|
td
|
5
|
|
td
|
2.65
|
|
td
|
> 2.80
|
|
td
|
0.10
|
|
td
|
0.10
|
|
tr
|
5 M 77 DM, CKD, AHT, pemphigus foliaceus 9 10 2 2.79 2.79 0.10 0.10
|
|
td
|
5
|
|
td
|
M
|
|
td
|
77
|
|
td
|
DM, CKD, AHT, pemphigus foliaceus
|
|
td
|
9
|
|
td
|
10
|
|
td
|
2
|
|
td
|
2.79
|
|
td
|
2.79
|
|
td
|
0.10
|
|
td
|
0.10
|
|
tr
|
6 M 55 HIV, AHT, hyperchol 8 9 13 0.69 0.69 0.18 0.80
|
|
td
|
6
|
|
td
|
M
|
|
td
|
55
|
|
td
|
HIV, AHT, hyperchol
|
|
td
|
8
|
|
td
|
9
|
|
td
|
13
|
|
td
|
0.69
|
|
td
|
0.69
|
|
td
|
0.18
|
|
td
|
0.80
|
|
tr
|
7 M 75 AML, IPA (2012) 3 3 8 2.63 2.63 N/A N/A
|
|
td
|
7
|
|
td
|
M
|
|
td
|
75
|
|
td
|
AML, IPA (2012)
|
|
td
|
3
|
|
td
|
3
|
|
td
|
8
|
|
td
|
2.63
|
|
td
|
2.63
|
|
td
|
N/A
|
|
td
|
N/A
|
|
table
|
Patient ID Sex (M/F) Age Medical history First positive culture CT scan Histological examinationa IPA diagnosis AspICU algorithm Antifungal therapy Outcome
1 M 86 Hyperchol A. flavus (ETA) No scan available N/A – – None Died, ICU day 10
2 M 38 Obesity, hyperchol A. fumigatus (BAL) + Positive Proven Absolute Voriconazole, isavuconazole Alive on MV, ICU day 28b
3 M 62 DM A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Died, ICU day 20
4 M 73 DM, obesity, AHT, hyperchol A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Alive on MV, ICU day 24b
5 M 77 DM, CKD, AHT, pemphigus foliaceus A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Alive on MV, ICU day 21b
6 M 55 HIV, AHT, hyperchol Negative No scan available Negative – Voriconazole, isavuconazole Died, ICU day 27
7 M 75 AML, IPA (2012) A. fumigatus (BAL) No scan available N/A – Voriconazole Died, ICU day 8
|
|
tr
|
Patient ID Sex (M/F) Age Medical history First positive culture CT scan Histological examinationa IPA diagnosis AspICU algorithm Antifungal therapy Outcome
|
|
th
|
Patient ID
|
|
th
|
Sex (M/F)
|
|
th
|
Age
|
|
th
|
Medical history
|
|
th
|
First positive culture
|
|
th
|
CT scan
|
|
th
|
Histological examinationa
|
|
th
|
IPA diagnosis
|
|
th
|
AspICU algorithm
|
|
th
|
Antifungal therapy
|
|
th
|
Outcome
|
|
tr
|
1 M 86 Hyperchol A. flavus (ETA) No scan available N/A – – None Died, ICU day 10
|
|
td
|
1
|
|
td
|
M
|
|
td
|
86
|
|
td
|
Hyperchol
|
|
td
|
A. flavus (ETA)
|
|
td
|
No scan available
|
|
td
|
N/A
|
|
td
|
–
|
|
td
|
–
|
|
td
|
None
|
|
td
|
Died, ICU day 10
|
|
tr
|
2 M 38 Obesity, hyperchol A. fumigatus (BAL) + Positive Proven Absolute Voriconazole, isavuconazole Alive on MV, ICU day 28b
|
|
td
|
2
|
|
td
|
M
|
|
td
|
38
|
|
td
|
Obesity, hyperchol
|
|
td
|
A. fumigatus (BAL)
|
|
td
|
+
|
|
td
|
Positive
|
|
td
|
Proven
|
|
td
|
Absolute
|
|
td
|
Voriconazole, isavuconazole
|
|
td
|
Alive on MV, ICU day 28b
|
|
tr
|
3 M 62 DM A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Died, ICU day 20
|
|
td
|
3
|
|
td
|
M
|
|
td
|
62
|
|
td
|
DM
|
|
td
|
A. fumigatus (BAL)
|
|
td
|
No scan available
|
|
td
|
Positive
|
|
td
|
Proven
|
|
td
|
Absolute
|
|
td
|
Voriconazole
|
|
td
|
Died, ICU day 20
|
|
tr
|
4 M 73 DM, obesity, AHT, hyperchol A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Alive on MV, ICU day 24b
|
|
td
|
4
|
|
td
|
M
|
|
td
|
73
|
|
td
|
DM, obesity, AHT, hyperchol
|
|
td
|
A. fumigatus (BAL)
|
|
td
|
No scan available
|
|
td
|
Positive
|
|
td
|
Proven
|
|
td
|
Absolute
|
|
td
|
Voriconazole
|
|
td
|
Alive on MV, ICU day 24b
|
|
tr
|
5 M 77 DM, CKD, AHT, pemphigus foliaceus A. fumigatus (BAL) No scan available Positive Proven Absolute Voriconazole Alive on MV, ICU day 21b
|
|
td
|
5
|
|
td
|
M
|
|
td
|
77
|
|
td
|
DM, CKD, AHT, pemphigus foliaceus
|
|
td
|
A. fumigatus (BAL)
|
|
td
|
No scan available
|
|
td
|
Positive
|
|
td
|
Proven
|
|
td
|
Absolute
|
|
td
|
Voriconazole
|
|
td
|
Alive on MV, ICU day 21b
|
|
tr
|
6 M 55 HIV, AHT, hyperchol Negative No scan available Negative – Voriconazole, isavuconazole Died, ICU day 27
|
|
td
|
6
|
|
td
|
M
|
|
td
|
55
|
|
td
|
HIV, AHT, hyperchol
|
|
td
|
Negative
|
|
td
|
No scan available
|
|
td
|
Negative
|
|
td
|
–
|
|
td
|
Voriconazole, isavuconazole
|
|
td
|
Died, ICU day 27
|
|
tr
|
7 M 75 AML, IPA (2012) A. fumigatus (BAL) No scan available N/A – Voriconazole Died, ICU day 8
|
|
td
|
7
|
|
td
|
M
|
|
td
|
75
|
|
td
|
AML, IPA (2012)
|
|
td
|
A. fumigatus (BAL)
|
|
td
|
No scan available
|
|
td
|
N/A
|
|
td
|
–
|
|
td
|
Voriconazole
|
|
td
|
Died, ICU day 8
|
|
table-wrap-foot
|
CKD chronic kidney disease, AML acute myeloid leukaemia, IPA invasive pulmonary aspergillosis. N/A no sample available, Hyperchol hypercholesterolaemia, AHT arterial hypertension, DM diabetes mellitus, BAL bronchoalveolar lavage, ETA endotracheal aspirate, MV mechanical ventilation arterial hypertension
aAnatomopathological examination of tissue samples obtained via bronchoscopy
bAt the time of writing
|
|
p
|
CKD chronic kidney disease, AML acute myeloid leukaemia, IPA invasive pulmonary aspergillosis. N/A no sample available, Hyperchol hypercholesterolaemia, AHT arterial hypertension, DM diabetes mellitus, BAL bronchoalveolar lavage, ETA endotracheal aspirate, MV mechanical ventilation arterial hypertension
|
|
p
|
aAnatomopathological examination of tissue samples obtained via bronchoscopy
|
|
p
|
bAt the time of writing
|
|
p
|
Our suspicion was raised initially through an unusually rapid growth (< 48 h) of Aspergillus species in bronchial aspirates of three different patients. All samples were obtained during routine bronchoscopies, performed for atelectasis, respiratory deterioration or increasing inflammatory parameters. From that moment, routine galactomannan assays on serum and bronchoalveolar lavage (BAL) fluid were assessed regularly and bronchoscopy-guided biopsies of suspicious tracheobronchial lesions were obtained whenever present. Unfortunately, computed tomography (CT) scanning was deemed unfeasible in some patients due to extreme hypoxia or difficult mechanical ventilation and whenever performed, the distinction between COVID-19 and Aspergillus lesions proved complex.
|
|
p
|
Table 1 shows the timing and results of the microbiological testing in our case series. Differentiating between Aspergillus colonization and IPA is notoriously difficult, especially in the ICU. In the absence of host factors, as defined by the European Organisation for Research and Treatment of Cancer (EORTC) diagnostic criteria, invasive or high-risk diagnostics (biopsy, CT scan) are required to support the diagnosis of IPA [7]. The AspICU algorithm was designed to partially deal with the absence of host factors [6]. Based on this algorithm, four patients (No 2, 3, 4, 5) were diagnosed with proven IPA, based on histopathological evidence. All of these patients showed positive galactomannan indices on BAL fluid. In two patients, cultures and/or galactomannan BAL only became positive post mortem (No 1, 7), before CT scan or histopathological samples could be obtained. In one patient (No 6), histopathological sampling was negative and galactomannan BAL only mildly raised, but a raised serum galactomannan was later detected. In the remaining patients, the serum galactomannan index remained negative (< 0.5). The mean time between intubation date and the first microbiological signs of IPA was a striking 8 (SD 5) days.
|
|
p
|
ICU physicians often have to weigh the risks of further diagnostic tests against a delayed initiation of antifungal treatment, which is associated with mortality rates over 65% [6]. Because all patients with clinical features of possible IPA were suffering from severe respiratory failure and hemodynamic instability, we initiated antifungal therapy as soon as cultures or galactomannan assays were positive. Five patients were started on voriconazole. In two of these patients, the treatment was escalated to isavuconazole due to pancytopenia or undetectable voriconazole levels under continuous renal replacement therapy. Two patients died on treatment.
|
|
p
|
To confirm and control this alarming incidence of COVID-19-associated IPA, a number of measures were taken. Firstly, we ruled out an environmental source, by sampling room air and the oxygen and pressurized air supplies (MAS 100, Merck). Prior to COVID-19, the incidence of IPA in our ICU was not elevated. Nonetheless, high-efficiency particulate air filters (HEPA) (Halton Vita, Helsinki, Finland) were installed in the ICU. Secondly, all mechanically ventilated COVID-19 patients were screened systematically by performing serum galactomannan assays twice weekly. Whenever a bronchoscopy was needed, BAL galactomannan indices and mould cultures were requested, regardless of the indication for bronchoscopy. Finally, we initiated prophylactic nebulization of 12.5 mg of liposomal amphotericin B (Ambisome®, Gilead, Foster City, USA) in every mechanically ventilated patient without an established diagnosis of IPA [8]. Since the implementation of these measures, we have not encountered any new cases of IPA at the time of writing.
|
|
sec
|
Conclusion
Using this case series, we would like to raise awareness about COVID-19-associated pulmonary aspergillosis, in view of its potential detrimental outcome. We believe that a low threshold for screening, prophylaxis and early antifungal treatment is of paramount importance, especially since different immunosuppressive therapies have been suggested to treat patients suffering from this alarming condition.
|
|
title
|
Conclusion
|
|
p
|
Using this case series, we would like to raise awareness about COVID-19-associated pulmonary aspergillosis, in view of its potential detrimental outcome. We believe that a low threshold for screening, prophylaxis and early antifungal treatment is of paramount importance, especially since different immunosuppressive therapies have been suggested to treat patients suffering from this alarming condition.
|
|
back
|
Abbreviations
COVID-19 Coronavirus disease 2019
SARS-COV-2 virus Severe acute respiratory syndrome coronavirus 2
ICU Intensive care unit
IPA Invasive pulmonary aspergillosis
IAA Influenza-associated aspergillosis
ARDS Acute respiratory distress syndrome
h Hour
BAL Broncho-alveolar lavage
CT Computed tomography
EORTC European Organization for Research and Treatment of Cancer
AspICU Aspergillosis intensive care unit
No Number
SD Standard deviation
HEPA High-efficiency particulate air filters
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Acknowledgements
We want to thank our entire ICU team for their unwavering commitment during these challenging times.
Authors’ contributions
LR wrote the first draft of manuscript with input and revisions from NVR and NS. NS collected the data from the source documents. TVH and LR performed the literature search. PB and HD advised on the reporting of the clinical data; RN and HM on the reporting of the microbiological and infection prevention data. All authors had full access to all of the data. All authors read and approved the final manuscript.
Funding
None.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
Publication approval granted by the Ethics Committee.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
|
|
title
|
Abbreviations
|
|
p
|
Coronavirus disease 2019
|
|
p
|
Severe acute respiratory syndrome coronavirus 2
|
|
p
|
Intensive care unit
|
|
p
|
Invasive pulmonary aspergillosis
|
|
p
|
Influenza-associated aspergillosis
|
|
p
|
Acute respiratory distress syndrome
|
|
p
|
Hour
|
|
p
|
Broncho-alveolar lavage
|
|
p
|
Computed tomography
|
|
p
|
European Organization for Research and Treatment of Cancer
|
|
p
|
Aspergillosis intensive care unit
|
|
p
|
Number
|
|
p
|
Standard deviation
|
|
p
|
High-efficiency particulate air filters
|
|
footnote
|
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
|
|
p
|
Publisher's Note
|
|
p
|
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
|
|
ack
|
Acknowledgements
We want to thank our entire ICU team for their unwavering commitment during these challenging times.
|
|
title
|
Acknowledgements
|
|
p
|
We want to thank our entire ICU team for their unwavering commitment during these challenging times.
|
|
notes
|
Authors’ contributions
LR wrote the first draft of manuscript with input and revisions from NVR and NS. NS collected the data from the source documents. TVH and LR performed the literature search. PB and HD advised on the reporting of the clinical data; RN and HM on the reporting of the microbiological and infection prevention data. All authors had full access to all of the data. All authors read and approved the final manuscript.
|
|
title
|
Authors’ contributions
|
|
p
|
LR wrote the first draft of manuscript with input and revisions from NVR and NS. NS collected the data from the source documents. TVH and LR performed the literature search. PB and HD advised on the reporting of the clinical data; RN and HM on the reporting of the microbiological and infection prevention data. All authors had full access to all of the data. All authors read and approved the final manuscript.
|
|
notes
|
Funding
None.
|
|
title
|
Funding
|
|
p
|
None.
|
|
notes
|
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
|
|
title
|
Availability of data and materials
|
|
p
|
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
|
|
notes
|
Ethics approval and consent to participate
Publication approval granted by the Ethics Committee.
|
|
title
|
Ethics approval and consent to participate
|
|
p
|
Publication approval granted by the Ethics Committee.
|
|
notes
|
Consent for publication
Not applicable.
|
|
title
|
Consent for publication
|
|
p
|
Not applicable.
|
|
notes
|
Competing interests
The authors declare that they have no competing interests.
|
|
title
|
Competing interests
|
|
p
|
The authors declare that they have no competing interests.
|
